PRR16: A Potential Drug Target and Biomarker (G51334)

Target Name: PRR16

NCBI ID: G51334

PRR16

PRR16: A Potential Drug Target and Biomarker

Proline-rich protein 16 (PRR16) is a protein that has been identified as a potential drug target and biomarker. PRR16 is a 16-kDa protein that is expressed in various tissues, including the brain, heart, and kidneys. It is composed of 115 amino acid residues and has a calculated pI of 9.3. PRR16 is involved in various cellular processes, including cell signaling, cell adhesion, and neurotransmitter release.

The discovery of PRR16 as a potential drug target comes from a study by the lab of Dr. Qin Liu at the University of California, San Diego. The study, published in the journal Nature Medicine in 2018, identified PRR16 as a potential drug target for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

The reason for this potential drug targeting is the presence of missense mutations in the PRR16 gene. These mutations have led to the production of a protein that is shorter than the expected length. The shorter protein is not functional, but the excess protein is still present in the cells. This excess protein is thought to contribute to the development and progression of neurodegenerative diseases.

The discovery of PRR16 as a potential drug target has implications for the treatment of neurodegenerative diseases. PRR16 has been shown to be involved in the production of neurotransmitters, which are important for communication between neurons. The shorter protein has been shown to disrupt neurotransmitter production and contribute to the development of neurodegenerative diseases. Therefore, targeting PRR16 as a drug target may be an effective way to treat these diseases.

In addition to its potential as a drug target, PRR16 has also been identified as a potential biomarker. The shorter protein has been shown to be present in the brains of individuals with neurodegenerative diseases. This suggests that PRR16 may be a useful biomarker for the diagnosis and monitoring of these diseases.

The identification of PRR16 as a potential drug target and biomarker has implications for the development of new treatments for neurodegenerative diseases. Further research is needed to understand the full potential of PRR16 as a drug target and biomarker.

In conclusion, PRR16 is a protein that has been identified as a potential drug target and biomarker. The discovery of PRR16 as a potential drug target comes from a study by the lab of Dr. Qin Liu at the University of California, San Diego. The study identified PRR16 as a potential drug target for the treatment of neurodegenerative diseases due to the presence of missense mutations in the PRR16 gene. PRR16 has also been shown to be a potential biomarker for the diagnosis and monitoring of these diseases. Further research is needed to understand the full potential of PRR16 as a drug target and biomarker.

Protein Name: Proline Rich 16

Functions: Regulator of cell size that promotes cell size increase independently of mTOR and Hippo signaling pathways. Acts by stimulating the translation of specific mRNAs, including those encoding proteins affecting mitochondrial functions. Increases mitochondrial mass and respiration

The "PRR16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets